Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).
Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
Beta-blockers have the greatest cardiovascular impact in patients with reduced heart
function/heart failure and in reducing the peri-operative risk of atrial fibrillation. In
patients without these high-risk features treated with coronary artery bypass graft (CABG)
surgery, their continued long-term role is unclear.